Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023

Rhea-AI Summary

Silence Therapeutics plc (NASDAQ: SLN) will announce its fourth quarter and full year financial results for the period ending December 31, 2022, on March 15, 2023. The company specializes in developing precision medicines via its proprietary mRNAi GOLD™ platform, leveraging RNA interference technology to target specific genes related to diseases. A conference call is scheduled for 8:00 a.m. EDT / 12:00 p.m. GMT on the same day to discuss the results and provide a business update. The call will be accessible via webcast on the company's website.

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2022, on Wednesday, March 15, 2023.

Management will host a conference call at 8:00 a.m. EDT / 12:00 p.m. GMT that day to discuss the Company’s financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the Company’s website.

Details of the webcast and conference call:

Webcast link: https://edge.media-server.com/mmc/p/7vduw4ku

Conference call registration link: https://register.vevent.com/register/BIbe6ada25ddb74c528acb36048aec7227

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005424/en/

Enquiries:

Silence Therapeutics plc

Gem Hopkins, Head of IR and Corporate Communications

ir@silence-therapeutics.com

Tel: +1 (646) 637-3208

Source: Silence Therapeutics plc

FAQ

When will Silence Therapeutics announce its financial results for the fourth quarter of 2022?

Silence Therapeutics will announce its financial results on March 15, 2023.

What time is the conference call for Silence Therapeutics' Q4 and full year results?

The conference call is scheduled for 8:00 a.m. EDT / 12:00 p.m. GMT on March 15, 2023.

How can I access the Silence Therapeutics conference call?

The conference call can be accessed via a live webcast on the Silence Therapeutics website.

What is Silence Therapeutics' stock symbol?

The stock symbol for Silence Therapeutics is SLN.

What technology does Silence Therapeutics use for drug development?

Silence Therapeutics uses its proprietary mRNAi GOLD™ platform to develop medicines using RNA interference technology.